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Abstract
Background: Hemophagocytic lymphohistiocytosis associated with autoimmune diseases is seen in patients with
systemic juvenile idiopathic arthritis, adult-onset Still’s disease, and systemic lupus erythematosus, whereas it is
rarely seen in patients with dermatomyositis. In addition, central nervous system involvement with dermatomyositis
is rare. To the best of our knowledge, this is the first case of hemophagocytic lymphohistiocytosis complicated
by leukoencephalopathy in a patient with dermatomyositis accompanied with peripheral T-cell lymphoma.
Case presentation: A 17-year-old Asian male adolescent with dermatomyositis and hemophagocytic
lymphohistiocytosis that were controlled with corticosteroid therapy presented to our hospital with high fever
and altered consciousness. Brain magnetic resonance imaging revealed multiple cerebral lesions. We diagnosed
the central nervous system lesions as leukoencephalopathy secondary to dermatomyositis and hemophagocytic
lymphohistiocytosis. Because corticosteroid and cyclophosphamide pulse therapy was ineffective, he was treated
with a modified hemophagocytic lymphohistiocytosis-2004 protocol, which resulted in the disappearance of the
lesions of his central nervous system.
Conclusions: Our findings suggest that the hemophagocytic lymphohistiocytosis-2004 protocol including
etoposide should be initiated immediately in patients with hemophagocytic lymphohistiocytosis who respond
poorly to treatment for the underlying disease. Moreover, irrespective of the underlying disease, patients with
hemophagocytic lymphohistiocytosis with central nervous system lesions might require bone marrow
transplantation.
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Background
Hemophagocytic lymphohistiocytosis (HLH) is a life-
threatening hyperinflammatory syndrome associated with
a variety of underlying conditions. The hereditary form of
HLH is caused by defects in the transport, processing, and
function of cytotoxic granules in natural killer cells and
cytotoxic T lymphocytes, and it can manifest in childhood
or adulthood. The acquired forms of HLH are caused by
infectious diseases, autoinflammatory and autoimmune
diseases, malignancies, and acquired immune deficiency
[1]. HLH associated with autoimmune diseases is seen in
patients with systemic juvenile idiopathic arthritis, adult-
onset Still’s disease, and systemic lupus erythematosus,
whereas it is rarely seen in patients with dermatomyositis
(DM) [2]. HLH is usually treated with intensive immuno-
suppressive therapy, including immunomodulatory and
immunosuppressive agents. The therapy aims to suppress
hypercytokinemia and to eliminate activated and infected
cells. The protocol based on HLH-1994/HLH-2004 (with
or without cyclosporine A in the first 8 weeks) is currently
regarded as the standard of care [3, 4]. Patients with
hereditary HLH can be cured only with hematopoietic
stem cell transplantation, while patients with acquired
HLH have shown improved survival when treated with
reduced-intensity conditioning regimens [1].
DM is an idiopathic acute inflammatory disorder,
characterized by inflammation of skeletal muscle, pro-
gressive symmetrical proximal myopathy, and classical
cutaneous manifestations. The disease is associated with
a connective tissue disease or a malignancy [5]. Central
nervous system (CNS) involvement with DM is rare, and
to the best of our knowledge, only five cases have been
reported that were associated with juvenile DM, which is
a rare, serious autoimmune condition of childhood invol-
ving systemic small vessel vasculopathy. It typically affects
skin and muscle, but it can also involve the joints, gut,
lung, heart, and other internal organs [6].
Case presentation
A 17-year-old Asian male adolescent was admitted to our
hospital with a chief complaint of sudden-onset fever and
altered consciousness. He had a 6-month history of DM
complicated by HLH controlled with corticosteroids (60
mg daily) and no obvious family, psychosocial, and genetic
history. At the time of diagnosis (6 months prior to admis-
sion), heliotrope eruption was seen. A blood examination
showed no evidence of myositis-specific antibody (anti-ami-
noacyl antibody). A muscle biopsy revealed lesions that
were consistent with myositis; he met the diagnostic criteria
of DM. A positron emission tomography-computed tomog-
raphy (PET-CT) examination (Fig. 1), bone marrow exam-
ination, and liver biopsy had shown no malignancy;
therefore, his corticosteroid dose was gradually reduced to
8 mg daily. However, he experienced intermittent leg
pain, and laboratory data showed a gradual elevation of
creatine kinase (CK) levels and progression of leukopenia
over the preceding 6 months; therefore, his steroid therapy
was increased to 30 mg daily.
On the day of admission, he was irritable, but there were
no remarkable findings on physical examination. Labora-
tory data showed increased levels of CK (1869 U/L), sol-
uble interleukin-2 receptor (4120 U/mL), and ferritin
(967.4 ng/mL) and decreased counts of white blood cells
(3910/μL) and platelets (124,000/μL). C-reactive proteins
were hardly detected (0.01 mg/dL). We suspected exacer-
bation of DM and HLH. Active hemophagocytosis and no
malignancy were observed on bone marrow examination.
Brain magnetic resonance imaging (MRI) revealed mul-
tiple bilateral subcortical lesions (Fig. 2). Systemic com-
puted tomography (CT) did not show any evidence of
interstitial pneumonia or malignancy. Cerebrospinal fluid
(CSF) aspiration revealed the presence of 12 cells (nine
LR
Fig. 1 A positron emission tomography-computed tomography
examination at the onset of dermatomyositis and hemophagocytic
lymphohistiocytosis. No mass lesions was detected
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neutrophils and 3three lymphocytes), glucose levels of 57
mg/dL, protein levels of 44 mg/dL, adenosine deaminase
levels of 3.9 (>1) U/L, and interleukin-6 levels of 91.9
(>4.3) pg/mL. Polymerase chain reaction (PCR) analyses
of his CSF showed no evidence of a recent infection with
the Epstein–Barr virus, cytomegalovirus, varicella zoster
virus, human herpes virus 6, and herpes simplex virus. We
could not perform a PET-CT examination on admission
because of his altered consciousness. On the basis of the
MRI findings, elevation of CSF interleukin-6 levels, per-
ipheral blood cell count, and biochemistry results, and the
hemophagocytosis observed in the bone marrow, we diag-
nosed the CNS lesions as leukoencephalopathy secondary
to DM and HLH.
The clinical course of our patient is presented in Fig. 3.
Dexamethasone (DEX) pulse therapy (20 mg daily for 3
days) and intravenous immunoglobulin therapy (400
mg/kg/day for 5 days) were initiated on the day of
admission to treat his CNS lesions. Methylprednisolone
(mPSL; 60 mg daily) was administered post-treatment.
His CK levels improved rapidly (from 1869 U/L on the
day of admission to 287 U/L on day 14); however, his
bicytopenia (leukopenia and thrombopenia) remained
unchanged, and his CNS lesions were still observed.
Therefore, cyclophosphamide pulse therapy was added
on day 8. On day 24, a second bone marrow exami-
nation revealed that his hemophagocytosis remained, for
which cyclosporine was started the next day. On day 28,
the 60 mg daily mPSL was changed to 20 mg daily DEX
because DEX diffuses to the CSF more easily than does
mPSL. In addition, as his hemophagocytosis persisted,
etoposide (120 mg/body) was started on day 38 and was
administered once per week between days 38 to 89
(eight times in total). On day 47, tacrolimus was
Fig. 2 Brain magnetic resonance imaging on the day of admission and on day 261 (showing recurrence). a–c Images on the day of admission;
d–f images obtained on day 261 when the patient’s central nervous system symptoms deteriorated. a and d Diffusion-weighted sequences
images. b and e Apparent diffusion coefficient images. c and f Fluid-attenuated inversion recovery images. a, b, d, e show that central nervous
system lesions did not derive from vasculitis and cerebrovascular diseases because those were not along the vessels. Hyperintensity in the cortex
and subcortical white matter can be seen in c and f. c Margins of the lesion are clearly visualized. f Margins of the lesion are unclear
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administered instead of cyclosporine to suppress hemo-
phagocytosis because both drugs have the same effects
and because of a severe liver function disorder due to
cyclosporine (aspartate transaminase and alanine
transaminase levels increased to 318 and 917 IU/mL, re-
spectively). Subsequently, his bicytopenia (leukopenia and
thrombopenia) recovered to within normal ranges, and his
CNS lesions disappeared.
He was administered sedative drugs to produce a state
of calmness, to help him sleep, and to prevent acts of
violence caused by his altered state of consciousness that
lasted for 5 months. The medications were eventually
discontinued because altered consciousness was no
longer observed. However, disturbances of his higher
cerebral functions remained. Five months after his initial
admission, he could speak and walk like a very young
child. Corticosteroid therapy was successfully tapered
without a relapse of his symptoms (including fever and
altered consciousness), and without changes in his
laboratory and MRI findings.
Eight months after admission, a follow-up brain MRI
revealed a recurrence of the CNS lesions (Fig. 2),
although these recurrent lesions were different from the
previous lesions, considering that there was no fever and
no altered consciousness. Moreover, his laboratory find-
ings were normal. We hypothesized that the pathology
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Fig. 3 Clinical course of the patient. The patient’s central nervous system lesions disappeared completely on day 143 after treatment with
methylprednisolone pulse therapy, cyclophosphamide administered intravenously, tacrolimus, and etoposide. However, he experienced a
recurrence of the lesions and ultimately died of sepsis on day 348. Laboratory data show that from day 0 to day 80 his white blood cells and
platelets decreased and increased. His creatine kinase levels reached a normal range at an early stage, and his soluble interleukin-2 receptor and
lactate dehydrogenase levels, biomarkers of malignant lymphoma, were almost normal throughout. In the early stage, we could not distinguish
his central nervous system lesions from central nervous system infectious disease owing to hemophagocytic lymphohistiocytosis with dermatomyositis;
therefore, we administered meropenem and acyclovir. In the first 5 months, we administered sedatives, such as propofol and dexmedetomidine, and
antiepileptic drugs, such as phenytoin and levetiracetam. Ara-c cytarabine, CK creatine kinase, CSF cerebrospinal fluid, DEX dexamethasone, IL-6 interleukin-6,
IVCY cyclophosphamide administered intravenously, IVIG intravenous immunoglobulin, LDH lactate dehydrogenase; MA therapy combination therapy with
methotrexate and cytarabine, MKC megakaryocyte, mPSL methylprednisolone, MTX methotrexate, NCC nuclear cell count, PLT platelet, PSL prednisolone,
sIL-2R soluble interleukin-2 receptor, WBC white blood cell
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of the new CNS lesions differed from the pathology of
the previous lesions and presumed that they were caused
by progressive multifocal leukoencephalopathy or drug-
induced (tacrolimus) leukoencephalopathy. However, a
PCR analysis for the John Cunningham virus in his CSF
(to diagnose progressive multifocal leukoencephalopathy)
was negative, and no improvement in CNS lesions was
observed when tacrolimus was discontinued.
One month after the recurrence of the CNS lesions, his
abilities to walk and speak deteriorated. A MRI revealed a
progression of the CNS lesions; therefore, a brain biopsy
of his right frontal lobe was performed on day 297. On
day 325, a diagnosis of peripheral T-cell lymphoma
(PTCL) was made based on the T-cell receptor rearrange-
ment seen in the tumor cells of his brain specimen.
Therefore, on day 330, chemotherapy combined with
high-dose methotrexate and cytarabine was initiated. A
follow-up MRI on day 345 revealed that his CNS lesions
had increased in size, suggesting that the chemotherapy
regimen was ineffective, and he died of sepsis on day 348.
An autopsy revealed yellowish to brownish extended
geographic lesions with softening, atrophy, and cavita-
tion in the white matter of the frontal, temporal, and
occipital lobes. Hepatomegaly (1910 g) and splenomegaly
(205 g) were also observed. Microscopy of the cerebral
white matter showed bilateral extended multiple lique-
faction necroses (Fig. 4a). Infiltration of predominantly
CD8(+) T cells undergoing dyskaryosis or mitosis was
observed in the Virchow–Robin space (Fig. 4b, c), bone
marrow, liver, and spleen. The rearrangements of the
TCR gene were confirmed by PCR of a brain specimen.
Hemophagocytosis was observed in the spleen and bone
marrow. On immunohistochemistry, no cells were posi-
tive for herpes simplex virus or John Cunningham virus,
and Epstein–Barr virus-encoded ribonucleic acid in situ
hybridization was negative.
Discussion
The patient presented here had a combination of several
very rare diseases (DM, HLH, and CNS lesions). His
condition was refractory, but it could be improved
through intensive chemotherapy including etoposide
(the modified HLH-2004 protocol).
Typically, most CNS lesions that appear acutely during
immunosuppressive therapy are caused by infection.
However, in this case, no infectious diseases were iden-
tified. Next, we suspected that the CNS lesions were
caused by DM; however, his brain MRI findings revealed
no evidence of vasculopathy or vasculitis, which are
often seen in CNS lesions due to juvenile DM [7, 8].
Neuropsychiatric systemic lupus erythematosus was also
excluded through blood and CSF examinations. Finally,
we considered that the patterns of the CNS lesions on
MRI closely resembled CNS lesions in patients with
hereditary HLH who exhibit diffuse leptomeningeal and
perivascular enhancement (corresponding to meningeal
and perivascular infiltrations of histiocytes and lympho-
cytes), patchy areas of increased T2 signal intensity in
the white matter of both cerebral hemispheres, and a
diffuse parenchymal volume loss of the cerebrum and
cerebellum [9]. Henter and Elinder described cases of
progressive encephalopathy (termed CNS-HLH in their
(a) (b)
(c)
Fig. 4 Brain biopsy findings. Brain tissue was stained with hematoxylin and eosin. a A brain lesion is distinguishable from the normal brain tissue.
Magnification ×40. b Perivascular lymphocytic infiltrations is seen. Magnification ×100. c Some mitotic changes are observed (arrow). Magnification ×400
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report) that were diagnosed on brain necropsy. The
pathophysiology of CNS-HLH has been characterized as
a perivascular infiltration of lymphocytes and histiocytes
in the cerebral parenchyma [10].
CNS involvement is commonly seen in patients with
hereditary HLH [11]. However, CNS involvement is less
commonly seen in patients with autoimmune-associated
HLH than in patients with malignancy-associated and
viral infection-associated HLH. Gupta et al. reported
that HLH was associated with rheumatic disease, malig-
nancy, and viral/other complications by CNS disease in
14 %, 38 %, and 31 % of cases, respectively [12]. In our
patient, natural killer cell activity was normal, and protein
levels of Munc13-4, Munc18-2, syntaxin 11, and integrin
αIIβ were normal; mutations in the genes coding for these
proteins are associated with the onset of hereditary HLH
[1]. Kim et al. reported that CNS involvement was asso-
ciated with poor outcomes in patients with HLH and
emphasized that the timely administration of chemo-
therapy (especially the early use of cyclosporine) was
important for improving survival [13].
Yamashita et al. reported a case of HLH associated
with DM complicated by CNS lesions; this case was
identified on a postmortem examination [14]. Similar to
our case, induction therapy, a combination of DEX pulse
therapy and cyclophosphamide pulse therapy, and cyclo-
sporine therapy was used in their patient. However, in
contrast to Yamashita et al. [14] who used corticos-
teroids, cyclosporine, and cyclophosphamide, we used
etoposide in accordance with the modified HLH-2004
protocol. We believe that the CNS lesions caused by
HLH in our case improved owing to the early treatment
based on the HLH-2004 protocol.
Haddad et al. have described the poor outcomes of
CNS disease in patients with HLH. According to the
results of their study, bone marrow transplantation
(BMT) appears to be the only available treatment pro-
cedure capable of preventing HLH CNS disease progres-
sion and that can cure the patient when performed early
after remission [11]. BMT was not performed after the
recurrence of the CNS lesions in our case. In hindsight,
considering the results, we should have performed BMT
after the CNS lesions disappeared. The reason that we
did not perform BMT was that there was no evidence
for the effectiveness of BMT for HLH associated with
autoimmune diseases complicated by CNS lesions, and
those lesions had completely disappeared on MRI. Pa-
tients with DM are often known to have malignancies [5].
In our case, no malignancies were found on the PET-CT
examination at the time of diagnosis of DM and HLH. We
could not confirm the coexistence of PTCL on the day of
admission because PET-CT examination and brain biopsy
were not performed. Nevertheless, considering that the
CNS lesions disappeared after the initial therapy and that
PTCL cannot be controlled by immunochemotherapy
according to the HLH-2004 protocol, we speculate that
the initial CNS lesions were not from PTCL. If the CNS
lesions had been derived from PTCL, it is unlikely that the
CNS lesions would have disappeared with treatment
following the HLH-2004 protocol. To the best of our
knowledge, there is no report in the literature that PTCL
complicated by CNS lesions could be cured by treatment
following the HLH-2004 protocol. Therefore, we
hypothesize that our patient experienced T-cell lymphoma
either as an adverse effect of immunosuppressant therapy
or due to chronic inflammation during his clinical course.
Conclusions
Our findings show that it is necessary to immediately
administer additional intensive immunosuppressive ther-
apies, such as those indicated in the HLH-2004protocol,
including etoposide, to patients with corticosteroid-
resistant acquired HLH due to autoimmune disease. In
addition, a biopsy should be performed as early as possible
for brain lesions of unknown origin. Patients with HLH
with CNS lesions might require BMT to achieve good
clinical outcomes.
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